Back to the list
Congress: ECR25
Poster Number: C-22116
Type: Poster: EPOS Radiologist (educational)
DOI: 10.26044/ecr2025/C-22116
Authorblock: C. R. Del Blanco, A. Leza , M. D. Garmendia Aguilar, B. Jiménez García-Carriazo, P. E. Pizano Ospina, C. Sánchez Rodríguez, E. Olivares Vivancos, M. Fernández Díaz, B. Magin Mingorance; Madrid/ES
Disclosures:
Celia Robles Del Blanco: Nothing to disclose
Agustin Leza : Nothing to disclose
Maria Dolores Garmendia Aguilar: Nothing to disclose
Begoña Jiménez García-Carriazo: Nothing to disclose
Paola Eugenia Pizano Ospina: Nothing to disclose
Coral Sánchez Rodríguez: Nothing to disclose
Eduardo Olivares Vivancos: Nothing to disclose
Martín Fernández Díaz: Nothing to disclose
Benigno Magin Mingorance: Nothing to disclose
Keywords: Abdomen, Liver, Oncology, CT, MR, Education, Staging, Cancer, Cirrhosis, Education and training
Learning objectives To learn how to use the two new 2024 LI-RADS Treatment Response Assessment (LI-RADS TRA) algorithms. To understand the main differences between these two algorithms and the 2018 version. To recognise the key limitations of the previous 2018 LI-RADS TRA.
Read more Background In 2018, the first LI-RADS Treatment Response Assessment (TRA) algorithm was published to help radiologists assess the response of hepatocellular carcinoma after locoregional treatment. This algorithm allows imaging findings to be classified into four different diagnostic categories: LR-TR Nonevaluable: If treatment response cannot be evaluated due to image degradation or omission. LR-TR Nonviable: If probably or definitely not viable. LR-TR Viable: If equivocally viable. LR-TR Equivocal: If probably or definitely viable. Follow-up CT or MRI scans are usually performed three months after treatment, although one-month...
Read more Findings and procedure details Updates to the 2024 LI-RADS Treatment Response Assessment AlgorithmAfter six years of using the 2018 LI-RADS Treatment Response Assessment (LI-RADS TRA) algorithm, multiple questions and limitations have emerged. Consequently, evidence-based studies have been conducted for validation. Following this research, several key statements can be made: APHE is the only imaging feature that has demonstrated a true diagnostic yield in confirming viability. The LI-RADS algorithm has shown good reliability in classifying patients treated with locoregional therapies into viable and non-viable categories. However, the...
Read more Conclusion The two new 2024 LI-RADS radiation and non-radiation TRA cores are a result of a revised and improved 2018 version that incorporates the latest evidence. These updates are designed to facilitate usage for radiologists and better categorize patients, which directly impacts management and outcomes.
Read more References Aslam A, Chernyak V, Miller FH, Bashir M, Do R, Sirlin C, et al. CT/MRI LI-RADS 2024 update: Treatment Response Assessment. Radiology [Internet]. 2024;313(2). Disponible en: http://dx.doi.org/10.1148/radiol.232408 Acrdsi.org. [citado el 16 de febrero de 2025]. Disponible en: https://aicentral.acrdsi.org/-/media/ACR/Files/RADS/LI-RADS/LI-RADS-CTMR-Radiation-TRA-v2024-Core.pdf Sitecorecloud.io. [citado el 16 de febrero de 2025]. Disponible en: https://edge.sitecorecloud.io/americancoldf5f-acrorgf92a-productioncb02-3650/media/ACR/Files/RADS/LI-RADS/LI-RADS-CTMR-Nonradiation-TRA-v2024-Core.pdf Sitecorecloud.io. [citado el 16 de febrero de 2025]. Disponible en: https://edge.sitecorecloud.io/americancoldf5f-acrorgf92a-productioncb02-3650/media/ACR/Files/RADS/LI-RADS/LI-RADS-CT-MRI-2018-Core.pdf Patel R, Aslam A, Parikh ND, Mervak B, Mubarak E, Higgins L, et al. Updates on LI-RADS treatment response criteria for hepatocellular carcinoma: Focusing...
Read more
GALLERY